Pemetrexed in small-cell lung cancer: Background and review of the ongoing GALES pivotal trial

Expert Review of Anticancer Therapy

Volumn 7, Issue 5, 2007, Pages 635-640

  Ferraldeschi, Roberta ^a   Thatcher, Nick ^a   Lorigan, Paul ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

GALES; Multitargeted antifolate; Pemetrexed; Small cell lung cancer

Indexed keywords

AMRUBICIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IRINOTECAN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; STEROID; THALIDOMIDE; TOPOTECAN; VINCRISTINE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PHARMACOGENOMICS; PLEURA MESOTHELIOMA; REVIEW; SIDE EFFECT; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; MESOTHELIOMA; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; ETOPOSIDE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; RANDOMIZED CONTROLLED TRIALS;

EID: 34248512233     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.5.635     Document Type: Review

References (31)

1. Kamangar F, Dores M, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2215 (2006).
2. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J. Clin. Oncol. 24(28), 4539-4544 (2006).
3. Socinski MA, Weissman C, Hart LL et al. Randomized Phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J. Clin. Oncol. 24(30), 4840-4847 (2006).
4. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6(4), 363-373 (2001). 5 Schutlz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res. 19, 437-443 (1999).
5. Shih C, Thornton DE. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In: Antifolate Drugs in Cancer Therapy. Jackman AL (Ed.). Humana Press, Totowa, NJ, USA 183-201 (1999).
6. Britten CD, Izbicka E, Hilsenbeck S et al. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother. Pharmacol. 44, 105-110 (1999).
7. Teicher BA, Chen V, Shih C et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. 6, 1016-1023 (2000).
8. Niyikiza C, Baker SD, Seitz ED et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1(7), 545-552 (2002).
9. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
10. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004).
11. Demarinis F, Paul S, Hanna N, Chang Yao Tsao T, Lim HL, Adachi S. Survival update for the Phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC). Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology June 2-6, Atlanta, GA, USA (2006) (Abstract 7133).
12. Chute JP, Chen T, Feigal F, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol. 17(6), 1794-1801 (1999).
13. Pujol JL, Carestia L, Daures J. Is there a case for cisplatin in the treatment of small cell lung cancer? A meta analysis of randomised trials of a cisplatin-containing regimen versus a regimen without this alkalylating agent. Br. J. Cancer 83(1), 8-15 (2000).
14. Mascaux C, Paesmans M, Berghmans T et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30(1), 23-36 (2000).
15. Bunn PA Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin. Oncol. 16(2 Suppl. 5), 27-33 (1989).
16. Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Phase II and III studies with carboplatin in small cell lung cancer. Semin. Oncol. 19(1 Suppl. 2), 28-36 (1992).
17. Thatcher N, Lind M. Carboplatin in small cell lung cancer. Semin. Oncol. 17(1 Suppl. 2), 40-48 (1990).
18. Brahmer JR, Ettinger DS. Carboplatin in the treatment of small cell lung cancer. Oncologist 3(3), 143-154 (1998).
19. Kosmidis PA, Samantas E, Fountzilas G et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized Phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin. Oncol. 21(3 Suppl. 6), 23-30 (1994).
20. Lassen U, Kristjansen PF, Osterlind K et al. Superiority of cisplatin or carboplatin in combination with temposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann. Oncol. 7, 365-371 (1996).
21. Hanna N, Ansari R, Bhatia S et al. Pemetrexed in patients with relapsed small cell lung cancer (SCLC). A Phase II study of the Hoosier Oncology Group. J. Clin. Oncol. 24(S18 Suppl. 1), 7063 (2006).
22. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive stage small-cell lung cancer. New Engl. J. Med. 346(2), 85-91 (2002).
23. Hanna N, Bunn PA, Langer C et al. Randomized Phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24(13), 2038-2043 (2006).
24. Eckardt JR, von Pawel J, Papai Z et al. Open-label, multicenter, randomized, Phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J. Clin. Oncol. 24(13), 2044-2051 (2006).
25. Reck M, von Pawel J, Macha HN et al. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised Phase III trial. Lung Cancer 53(1), 67-75 (2006).
26. Mavroudis D, Papadakis E, Veslemes M et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as front-line treatment in patients with small cell lung cancer. Ann Oncol. 12(4), 463-470 (2001).
27. Niell HB, Herndon JE II, Miller AA et al. Randomized Phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J. Clin. Oncol. 23(16), 3752-3759 (2005).
28. James LE, Rudd R, Gower NH et al. A Phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC). Presented at: Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology. May 18-21, Orlando, FL, USA (2002) (Abstract 1170).
29. Ohe Y, Negoro S, Matsui K et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer. Ann. Oncol. 16(3), 430-436 (2005).
30. Yana T, Negoro S, Takada M et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest. New Drugs (2006) (Epub ahead of print).
31. Pujol JL, Breton JL, Gervais R et al. A prospective randomized Phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): an intergroup study FNCLCC Cleo04 - IFCT 00-01. Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. June 2-6, Atlanta, GA, USA (2006) (Abstract 7057).